10x Genomics (NASDAQ: TXG) narrows 2025 losses and guides to modest 2026 growth
10x Genomics reported significantly narrowed losses in 2025, driven by improved profitability and reduced operating expenses, despite only modest revenue growth. The company also provided cautious revenue guidance for 2026, projecting 0% to 4% growth when excluding one-time patent litigation settlement revenue from 2025. This financial update highlights a strategic shift towards profitability amidst a challenging market, supported by strong cash reserves and strategic partnerships.
https://www.stocktitan.net/sec-filings/TXG/8-k-10x-genomics-inc-reports-material-event-c478d34a021e.html